The purpose of this shared service is to support equipment maintenance for research equipment that is shared by cancer center members and used for peer-reviewed research projects. Many of the cancer center investigators rely on shared-use instruments. These particular instruments require some degree of supervision or expertise and, thus, are located in individual laboratories so that technical help in operating the instrument is readily available. Some of the equipment is used mainly by the occupants of a particular laboratory, while, in other instances, a piece of equipment is unique and the only one of its kind in the building or on the particular campus. This equipment is shared and available to all investigators who are members of the cancer center. The concept of shared equipment minimizes the efficient use of the instruments and ensures investigators the availability of instrumentation that would otherwise be beyond the financial means of their research projects. The majority of this instrumentation has been purchased with donations, grants, contracts, or departmental funds that are no longer available for continued support of the equipment. As a result, there are no funds to support preventive maintenance and repair. Because the equipment frequently has a large number of users, it is difficult to apportion the responsibility for maintenance. Cancer center support for this function has provided a measure of stability for equipment maintenance. The goals of this shared service are: * To ensure continued operation of research equipment used by cancer center investigators; * To maximize access by cancer center members to needed research equipment; * To provide an efficient mechanism for supporting needed research equipment without cutting into research dollars; and * To potentially achieve cost savings though contracts covering multiple pieces of equipment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-07
Application #
6237184
Study Section
Project Start
1997-08-01
Project End
1998-07-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
7
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :

Showing the most recent 10 out of 989 publications